Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors

B Clinical trial will evaluate safety, tolerability and antitumor activity of Repertoire’s novel off-the-shelf T cell receptor (TCR) bispecific therapy as monotherapy and in combination…
posteditor
posteditor
Articles: 27509

Other News